I note in the pre-clinical lab tests on mice that there were...

I note in the pre-clinical lab tests on mice that there were significant results:
"We obtained 100% protection with a codon-optimized, non-ubiquitinated gD2 construct"

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076407

Given US population is 300,000,000
Prevalence of HSV2 ~ 1 in 6
Which equates to 50,000,000 people infected
Assume a dose is a reasonable $100
Given theres no viable alternative assume 40% market penetration

Gives Revenue
50,000,000 x 0.40 x 100 = 2,000,000,000
2 Billion

Assume NPAT is 16%
2,000,000,000 x 0.16 = 320,000,000
320 Million

Assume another 50 million in shares is raised taking total to 250,000,000
Gives EPS
320,000,000 / 250,000,000 = 1.28

Assume P/E of 15
Gives a price
1.28 x 15 = 19.02

19.02 price target without including Cardiocel and Infusion products